Merck & Co., Inc. (NYSE:MRK) announced the data for its
investigational MK-7243 tablet from a Phase III clinical study involving 1,501
North American adult and pediatric patients. MK-7243 is a Timothy grass
sublingual allergy immunotherapy tablet that had been accepted by the U.S. Food
and Drug Administration for review Biologics License Applications alongside
that of ragweed pollen sublingual allergy immunotherapy tablet. The company
anticipates these reviews by the USFDA to be completed during 1H14. To develop the sublingual allergy
immunotherapy tablets, Merck had partnered with ALK-Abello.
The results for MK-7243 showed that the therapy demonstrated
significant improvement in TCS (Total Combined Score), DSS (Daily Symptom
Score) and DMS (Daily Medication Score) compared to placebo. Read more.
No comments:
Post a Comment